Astria Therapeutics' (ATXS) shares were up nearly 3% in recent Friday trading after JMP Securities initiated the company's stock at outperform.
This comes days after the company started its phase 1a clinical trial in healthy subjects of STAR-0310, a potential treatment for atopic dermatitis. Early proof-of-concept results are expected in Q3.
Trading volume stood at over 162,000 shares against a daily average of about 323,000 shares.
Price: 7.70, Change: +0.21, Percent Change: +2.80